Over 500 delegates attended the 2018 European Orthopaedic Research Society (EORS) Meeting in Galway.
The meeting was chaired by Dr Dimitrios I. Zeugolis, Director of the Regenerative, Modular and Developmental Engineering Laboratory, part of CÚRAM, the Science Foundation Ireland Centre for Research in Medical Devices in NUI Galway.
The conference provided a forum to discuss recent advances, challenges and opportunities in orthopaedic, musculoskeletal and trauma research and practice and attracted a broad cross-section of world-leading professionals from researchers in academia and industry, to clinicians and medical regulators.
Delegates attending the conference travelled from as far afield as Taiwan and New Zealand. Galway is a focused global centre of activity for world-leading companies in these fields such as Boston Scientific and Medtronic. The meeting is of strategic importance to Ireland, a country whose Medical Technology industry accounts for more than 10% of exports, €12.6 billion.
Trauma and orthopaedic treatments and surgery involve treating traumatic, developmental and degenerative conditions of the musculoskeletal system; novel and innovative techniques, implants and treatments are constantly being developed and applied to treat a very wide range of patients. As the population ages, the number and range of medical interventions taking place annually is increasing exponentially, as is the market for orthopaedic products.
Almost 70 new research papers were presented to delegates at this year’s meeting as well as plenary presentations from global leaders in the field, and five workshop sessions including Female Leadership and Stem Cells. Dedicated symposia include Fracture, Trauma, Failure, Clinical Trials and Obesity, and Diabetes and Fracture Healing.
Dr Dimitrios I. Zeugolis from CÚRAM at NUI Galway, said: “It is a great honour to host this prestigious meeting in Galway, that the programme is of an excellent standard.
“The meeting provides an opportunity to promote the high-value, high gains research and development taking place at NUI Galway and in the West of Ireland and is expected to translate as a €450,000 boost to local revenue.”
During one of the oral presentations Bone Therapeutics highlighted recent preclinical in vitroand in vivo results demonstrating the potent osteogenic properties of its allogeneic bone-forming cell therapy platform to promote bone-formation and improve fracture healing in relevant models.
Bone Therapeutics’ technology is based on a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.